Table 1.
Diagnostic characteristics of study patients, with baseline risk stratification
| All patients (N = 203) | B-ALL/LL (n = 139) | T-ALL/LL (n = 64) | P value | |
|---|---|---|---|---|
| Age (y), median (range) | 39.8 (18-65) | 41.0 (18.1-64.8) | 33.4 (18.5-65.1) | .089 |
| ≤40, n (%) | 103 (50.7) | 66 (47.5) | 37 (57.8) | .381 |
| 40-55, n (%) | 61 (30.0) | 44 (31.6) | 17 (26.5) | |
| >55, n (%) | 39 (19.2) | 29 (20.8) | 10 (15.6) | |
| Gender (male), n (%) | 118 (58.1) | 76 (54.6) | 42 (65.6) | .07 |
| Diagnosis, n (%) | ||||
| ALL | 183 (90) | 138 (99.2) | 45 (70.3) | <.001 |
| LL∗ | 20 (9.8) | 1 (0.8) | 19 (29.7) | |
| ECOG PS†, n | ||||
| 0:1:2:3:NA | 120:58:15:3:7 | 88;32;12;1 | 32;26;3;2 | |
| Hemoglobin (g/dL), median (range) | 9.5 (3.7-16.8) | 9.1 (3.7-16.2) | 11.5 (7.1-16.8) | <.000 |
| WBC count (109/L), median (range) | 7.1 (1.5-347.3) | 4.9 (1.5-347.3) | 11.2 (2.9-345.0) | .003 |
| ≤30 (%) | 159 (78.3) | 110 (79.1) | 49 (76.6) | .0367 |
| >30-100 (%) | 31 (15.27) | 24 (17.26) | 7 (10.94) | |
| >100 (%) | 13 (6.40) | 5 (3.60) | 8 (12.50) | |
| BM blasts (%), median (range) | 88.0 (0-100) | 90.0 (0-100) | 75.0 (0-100) | .0007 |
| PB blasts (%), median (range) | 41.0 (0-100) | 44.5 (0-100) | 27.0 (0-100) | .205 |
| Platelets (109/L), median (range) | 73.0 (1.2-630) | 57.0 (1.2-630) | 141.5 (7.0-476.0) | <.000 |
| Hepatomegaly, n (%) | 18 (14.9) | 14 (17.7) | 4 (10.5) | .416 |
| Splenomegaly, n (%) | 47 (28.7) | 36 (37.1) | 11 (25.0) | .157 |
| Lymphadenopathy, n (%) | 84 (45.4) | 35 (28.5) | 49 (79.0) | <.0001 |
| Mediastinal mass, n (%) | 36 (18.7) | 2 (1.55) | 34 (54.0) | <.0001 |
| CNS involvement, n (%) | 19 (9.3) | 12 (8.6) | 7 (10.9) | .635 |
| Other involved site, n | 4 | |||
| Testis/ovary (skin) | 2:2 | |||
| Immunophenotype, n (%) | ||||
| B: pro, common, pre, and undefined | 139 (68.4) | 20, 99, 10, and 9 | ||
| T: ETP, pro, pre, cortical, mature, and undefined/MPAL | 64 (31.6) | 14, 1, 10, 12, 2, and 6 | ||
| Cytogenetics/genetics, n (%) | ||||
| Normal | 57 (47.1) | 23 | 34 | |
| Adverse | 33 (27.3) | 32 | 1 | |
| t(4;11)/KMT2A::AFF4, t(11;19) | 16 | 16 | - | |
| Other‡ | 17 | 17 | 1 | |
| Nonadverse | 40 (31) | 36 | 4 | |
| t(1;19)/E2A::PBX1 | 4 | 4 | ||
| Hyperdiploid | 14 | 12 | 2 | |
| Other nonadverse | 22 | 20 | 2 | |
| Not evaluable | 73 (35.9) | 48 | 25 | |
| Ph-like signature (n = 88 studied)§ | 28 | 28 (31.8%) | ||
| Risk stratification, n (%) | ||||
| SR | 115 (56.7) | 83 (59.7) | 32‖ (50.0) | |
| HR | 20 (9.9) | 20 (14.4) | 0 | |
| VHR | 68 (33.4) | 36 (25.9) | 32 (50.0) |
ALL, acute lymphoblastic leukemia (BM blasts of >20%); BM, bone marrow; ECOG PS; Eastern Cooperative Oncology Group performance status; LL, lymphoblastic lymphoma (BM blasts of <20%); MPAL, mixed-phenotype acute leukemia (T cell/myeloid) (n = 1); NA, not available; NR, not reported; PB, peripheral blood.
Patients with LL (n = 20): stage I, n = 2; stage II, n = 4; stage III, n = 4; stage IV, n = 6; unreported, n = 4; and BM involvement (LL cells 5%-15%), n = 4.
ECOG PS score.
Other than t(4;11)/KMT2A rearrangement: 11q23, +8, −7, del6q, t(8;14) abnormalities, low hypodiploidy (30-39 chromosomes), near triploidy (60-78 chromosomes) or complex karyotype with ≥5 unrelated anomalies.
Ph-like signature not entered as HR/VHR baseline feature in original risk model.
Thirteen T-ALL and 19 T-LL.